These are likely to be clinically significant reductions as the risk of diabetes complications drops by 35% for every percentage point decrease in HbA1c.18 In short, an unanticipated positive effect of the TTR on the primary outcome may have been a key reason for the trial not showing a statistically significant difference between the arms. The gene discussed is TTR; the disease is diabetes mellitus.